Lymphoma, Non-Hodgkin: all 2,043 studies
Page 12 of 21. Open to participants first (309), then studies with results posted, then the rest; newest registration first within each.
- A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin LymphomaCompletedNCT04231747Phase 1
- Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin LymphomaWithdrawnNCT04220008Phase 2
- A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic LeukemiaCompletedNCT04210219Phase 1
- Study of CD19 Specific Chimeric Antigen Receptor Positive T Cells (CAR-T) in ALL and NHLStatus unknownNCT04206943Phase 1/2
- Resiliency in Older Adults Undergoing Bone Marrow TransplantCompletedNCT04188678
- The Clinical Study of CD20 CAR-T Cells in Patients With Relapsed and Refractory B Cell Non-Hodgkin LymphomaStatus unknownNCT04169932Early Phase 1
- Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell TransplantActive, not recruitingNCT04167683
- TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin LymphomaTerminatedNCT04161118Phase 2
- Non-invasive Evaluation of Lymphoma Patients Based on Artificial Intelligence and PET/MRIStatus unknownNCT04154228Not applicable
- A Phase I Clinical Trial of BAT4306F on Safety, Tolerability and Pharmacokinetics for PatientsCompletedNCT04152148Phase 1
- NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin LymphomaCompletedNCT04136756Phase 1
- CAR-37 T Cells in Hematologic MalignanciesCompletedNCT04136275Phase 1
- Study of PD-1 Monoclonal Antibody in Combination With Chemotherapy in Patients With RR NHLStatus unknownNCT04134247Phase 4
- ASTRAL- a Clinical Study to Assess the Efficacy and Toxicity of High-dose ChemotherapyCompletedNCT04121507Phase 2
- Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin LymphomaCompletedNCT04094142Phase 2
- Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin LymphomaCompletedNCT04089527Phase 1
- CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins LymphomaActive, not recruitingNCT04089215Phase 2
- Cost-Effectiveness Study of PEG-rhG-CSF in Prophylactic Treatment of Neutropenia After Chemotherapy in LymphomaStatus unknownNCT04083079Phase 4
- A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin LymphomaTerminatedNCT04082936Phase 1/2
- A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's LymphomaActive, not recruitingNCT04077723Phase 1/2
- An Individualized Physical Activity Program in Patients Over 65 Years With Hematologic MalignanciesCompletedNCT04052126Not applicable
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin LymphomaTerminatedNCT04045028Phase 1
- Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or LymphomaWithdrawnNCT04029038Phase 1/2
- FLT PET: A Pilot Study in Lymphoma PatientsCompletedNCT04028804
- γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)Status unknownNCT04028440Early Phase 1
- A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese PatientsActive, not recruitingNCT04024696Phase 1/2
- Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Non-Hodgkin LymphomaStatus unknownNCT04012892Phase 1
- CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic LeukemiaStatus unknownNCT04004637Phase 1
- A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell TransplantationActive, not recruitingNCT04002297Phase 3
- Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell LymphomaCompletedNCT03994913Phase 1/2
- Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic LeukemiaCompletedNCT03991884Phase 1
- Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's LymphomaCompletedNCT03974243Phase 1/2
- A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)Active, not recruitingNCT03930953Phase 1/2
- A Metagenome-wide Association Study of Gut Microbiota in Gastrointestinal Non-Hodgkin's Lymphoma PatientsStatus unknownNCT03930043
- Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and LymphomasWithdrawnNCT03925428Phase 1
- Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory LymphomaStatus unknownNCT03921879Phase 1
- A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic MalignanciesActive, not recruitingNCT03913949Phase 1
- Treatment of Children CD19+ Leukemia and Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell TherapyStatus unknownNCT03910842Early Phase 1
- Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)CompletedNCT03904134Not applicable
- A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)CompletedNCT03900598Phase 1
- A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's SyndromeActive, not recruitingNCT03899337Phase 2
- A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's LymphomasTerminatedNCT03893682Phase 1
- Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell LymphomaTerminatedNCT03892525Phase 1
- Outpatient Administration of R-DHAP in Relapsed/Refractory Non-Hodgkin LymphomaCompletedNCT03892421Phase 1/2
- Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.TerminatedNCT03886649Phase 1
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
- An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical TrialActive, not recruitingNCT03844048Phase 3
- Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow TransplantationActive, not recruitingNCT03842696Phase 1/2
- Blinatumomab Expanded T-cells (BET) in Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic LeukemiaStatus unknownNCT03823365Phase 1
- The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir AlafenamideTerminatedNCT03804372Phase 2
- Study of ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin LymphomaCompletedNCT03802955Phase 1
- A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic MalignanciesTerminatedNCT03797261Phase 1
- BuCE Versus BuME as Conditioning Therapy in Non-Hodgkin's LymphomaCompletedNCT03794167Phase 2
- Busulfan, Melphalan and Etoposide as Conditioning for Autologous Transplantation for Non-Hodgkin's Lymphoma (NHL)CompletedNCT03792815Phase 2
- Treatment of Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell TherapyStatus unknownNCT03790891Early Phase 1
- Vaccination With Flt3L, Radiation, and Poly-ICLCCompletedNCT03789097Phase 1/2
- MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell OriginStatus unknownNCT03778619Phase 1/2
- A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)WithdrawnNCT03772288Phase 1
- Registry of BrentuximabVedotinin Patients With R/R Anaplastic Large Cell Lymphoma or Classical HLCompletedNCT03766516
- Biomarkers in Primary Sjögren's SyndromeStatus unknownNCT03765593
- Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic LeukemiaTerminatedNCT03755154Phase 1
- A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHLCompletedNCT03740529Phase 1/2
- Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCART Cell TherapyStatus unknownNCT03720496Phase 1
- Azacitidine and Rituximab-GDP Immunochemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaStatus unknownNCT03719989Phase 2
- Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell LymphomaWithdrawnNCT03719898Phase 2
- Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin LymphomaCompletedNCT03713580Phase 1
- Study of CD137 Agonist ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin LymphomaCompletedNCT03707093Phase 1
- Integrated Discovery of New Immuno-Molecular Actionable Biomarkers for Tumors With Immune-suppressed EnvironmentCompletedNCT03706625
- Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell LymphomaSuspendedNCT03704714Phase 1/2
- Intrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin LymphomaStatus unknownNCT03688451Phase 2
- Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell LymphomaCompletedNCT03682796Phase 1
- 9-ING-41 in Patients With Advanced CancersActive, not recruitingNCT03678883Phase 2
- A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin LymphomaActive, not recruitingNCT03671018Phase 1/2
- MB-CART20.1 LymphomaCompletedNCT03664635Phase 1/2
- Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226)Status unknownNCT03639181Phase 2
- Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell TransplantActive, not recruitingNCT03622788Phase 1/2
- Patient Preference for Pegfilgrastim (Neulasta®) Application FormsCompletedNCT03619993Not applicable
- Chidamide Combined With Clad/Gem/Bu With AutoSCT in High Risk Hodgkin & Non-Hodgkin LymphomaStatus unknownNCT03602131Phase 2
- Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)TerminatedNCT03598608Phase 1/2
- Identifying Immune-related Biomarkers to Predict the Efficacy of Cancer ImmunotherapyCompletedNCT03595813Not applicable
- Extension of a Study of Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor to Younger Patients Eligible for Reduced-intensity Conditioning RegimenCompletedNCT03595800Phase 3
- Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic MalignanciesStatus unknownNCT03588598Phase 1
- CD19-Specific T Cells Post AlloSCTTerminatedNCT03579888Phase 1
- Rituximab Plus MG4101 Indolent CD20-positive Non-Hodgkin Lymphoma (NHL)TerminatedNCT03578198Phase 2
- A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDSCompletedNCT03573310Phase 1
- Study of Prognostic Factors in Adult Lymphoblastic LymphomaStatus unknownNCT03571997
- Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALLStatus unknownNCT03564704Phase 2/3
- A Clinical Trial of Decitabine in Relapsed or Refractory T-lymphoblastic LymphomaStatus unknownNCT03558412Phase 4
- An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's LymphomaActive, not recruitingNCT03533283Phase 1/2
- Assessment of Safety and Efficacy of IM19 for Relapsed or Refractory NHL PatientsStatus unknownNCT03528421Phase 1
- Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)CompletedNCT03527147Phase 1
- Copanlisib Chinese PK StudyCompletedNCT03498430Phase 1
- Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19Status unknownNCT03497533Phase 1/2
- A PhaseⅠb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL SubjectsCompletedNCT03483688Phase 1
- Subclinical Cardio-toxicities Evaluation With Strain Rate Echocardiography After Chemotherapy and/or Mediastinal Radiotherapy in Patient With LymphomaCompletedNCT03480087
- R-BL-M-04 Versus R-(DA)-EPOCH and Autologous Stem Cells Transplantation in Patients With High-Grade B-cell Lymphoma Double-hit (HGBL DH) and High-Grade B-cell Lymphoma Not Otherwise Specified (HGBL NOS)Status unknownNCT03479918Phase 3
- Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin LymphomaActive, not recruitingNCT03479268Phase 1
- Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and SarcomasActive, not recruitingNCT03478462Phase 1
- Unicentric Retrospective Analysis of a Cohort of 602 Young Adult and Adolescent Patients (AJA), Aged 15 to 30 Years, With Haematological Malignancies, and Managed Between 2000 and 2016CompletedNCT03469921
- A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCLCompletedNCT03467373Phase 1